//   Enhertu案件跨越周期、多个维度地揭示了跨境资产交易可能面临的IP战略盲区，以及足以扭转事态发展轨迹的法律细节。我们将用三篇文章的篇幅，分别从多维主体观望案件、IP策略与法律细节解构、BD交易的IP策略及法律风控指引三个方面，为读者深度解析Enhertu案。 撰文 | 路晓 近年来，中国生物医药产业凭借在全球ADC、双抗等领域的创新发展，迎来了跨境商业拓展（BD）与资产许可（License-in/out）的黄金时代。然而，在繁荣交易和诱人商机的背后，往往潜伏着知识产权（IP）权属划分和责任界限的深水暗礁。 2026年3月2日，Seagen与第一三共、阿斯利康围绕“ADC药王”Enhertu展开的历时7年、涉案数亿美元的系列知产争议案已尘埃落定。第一三共在经历2022年一审全面败诉的至暗时刻后，迎来了终审的绝地翻盘。 回望这场曲折跌宕的知产拉锯战，无论是许可方（Licensor）的Seagen、被许可方（Licensee）第一三共，还是后续加入合作开发（Co-develop）的阿斯利康，都曾面临令人唏嘘的惊心时刻：第一三共在亲手创造ADC神话后，遭遇老合作对手在底层专利层面

New wellness destination combines advanced brain health technology with aesthetic and restorative therapies SPRINGFIELD, Ill., June 16, 2026 /PRNewswire/ -- Blissful Essence Wellness Center today announced the launch of its comprehensive wellness and aesthetics center in Springfield, bringing the area's first EXOMIND treatment to the community while offering a range of services designed to support both physical and emotional well-being. Continue Reading EXOMIND is leading-edge therapy that tre

BOSTON and ROLLE, Switzerland, June 16, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, announced today the commencement of a proposed underwritten public offering of its ordinary shares. The Company also expects to grant the underwriters an option to purchase up to an additional 15% of the ordinary shares at the public offering price, less the underwriting discount. All of the ordinary shares to be sold in the proposed offering will be sold

New late-breaking data presentations underscore Jazz's significant progress in advancing holistic understanding of narcolepsy and idiopathic hypersomnia, including novel real-world evidence of meaningful changes in cardiometabolic risk markers following Xywav initiation For U.S. media and investors only DUBLIN, June 16, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced 11 late-breaking presentations at SLEEP 2026, including notable new research showcasing the comprehen

SOUTH SAN FRANCISCO, Calif., June 16, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the closing of its license agreement for VEPPANUTM (vepdegestrant), following the early termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976 and satisfaction of other customary closing conditions. Rigel previously announced it entered into an exclusiv

Research involving more than 1,600 participants shows significant improvements in pain, function, and well-being across diverse musculoskeletal populations NASHVILLE, Tenn., June 16, 2026 /PRNewswire/ -- Vori Health, the nationwide physician-led musculoskeletal (MSK) healthcare provider, today announced the publication of two peer-reviewed studies demonstrating significant improvements in pain and function among patients treated through its integrated virtual care model. The studies evaluated ou

中国医药企业管理协会（CPEA）于1985年7月成立，是全国性的、非营利性的社会团体法人组织，其业务指导部门为国务院国有资产监督管理委员会。协会的宗旨和工作总目标是：宣传贯彻党的各项方针政策，面向医药企业、为医药企业和医药企业家(经营管理者)服务。推动企业管理现代化和生产技术现代化。为探索和建立现代企业制度及符合社会主义市场经济规律的中国医药企业管理体系，为不断提高医药企业、医药企业家(经营管理者)素质开展各项工作，在政府和企业之间发挥桥梁和纽带作用。网址：http://www.cpema.org。 EHS管理专业委员会（EHS专委会）是中国医药企业管理协会的内设机构，2015年9月组建，致力于提升中国医药行业EHS管理水平，加快与国际先进水平接轨，促进中国医药行业可持续发展。协会特聘专家成立EHS专家组，编制和修订《中国制药工业EHS指南》，推动编制EHS相关的行业标准和团体标准，征集评选并发布制药企业EHS管理优秀实践案例，成立工作组针对EHS相关的法规向企业征集意见并反映给有关监管部门、每年组织召开“制药工业EHS管理年会”、搭建制药工业EHS管理同仁交流平台、组织线上EHS管理

EHS PHARMA GOOD PRACTICES 2025年制药企业EHS管理优秀案例 通知｜2025年“制药企业EHS管理优秀案例”征集评选活动启动 2025年制药企业EHS管理优秀案例获奖名单 南京药石科技股份浙江晖石药业 | 二氯甲烷废气耦合治理技术实践 勃林格殷格翰(BI)生物药业(中国)/ BI(中国)| 通勤道路安全评估 强生(中国)医疗器材 | AI智能安全摄像头在叉车中的应用与安全效能提升 浙江医药股份/昌海生物 | “污水零直排”数字化在昌海生物产业园区的应用 齐鲁制药(内蒙古)| 粉尘防爆技术革新改造升级 赛诺菲(北京)制药 | EPA化学品吸入风险评估模型在制药企业的应用 强生西安杨森制药 | 流动相制备自动化系统革新EHS管理 强生(中国)医疗器材 | 关于降噪与人机工效改善的职业健康实践 强生眼力健(杭州)制药 | 制药行业的智能检测转型：新技术助力提升生产安全与效率 10.扬子江药业集团江苏海慈生物 | 含氯VOCS废气治理项目 11.上海医药集团南通常佑药业 | 零成本搭建隐患上报管理系统 12.复星医药集团/上海复宏汉霖生物 | 精准监控与智能调控高效

Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies New microdose formats extend Optimi's psilocybin range, which includes a 5mg formulation currently commercially prescribed for treatment-resistant depression in Australia under the country's Authorized Prescriber Scheme VANCOUVER, BC, June 16, 2026 /PRNewswire/ - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the " Company" or " Op

HONG KONG, June 16, 2026 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor" or the "Company", Stock Code: 1833.HK) has recently upgraded its AI doctor service — Ping An AI Doctor. The service has been fully integrated into a number of core applications under Ping An Group, including Ping An Jin Guan Jia, Ping An Auto Owner, Ping An Pocket Bank and Ping An Le Health, reaching 90 million monthly active users. Powered by the Ping An Medical Master® large mode